Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Global Market Report 2020 REQUEST FOR SAMPLE REPORT Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit The benign prostatic hyperplasia (BPH) treatment devices and equipment market consists of sales of benign prostatic hyperplasia (BPH) treatment devices and equipment and related services. Benign prostatic hyperplasia or benign prostatic hypertrophy is a condition of an enlarged prostate gland which causes blockade of urethra, the tube that carries urine from the bladder. The market is segmented into resectoscopes, radiofrequency ablation device, urology lasers, prostatic stents and implants. The global benign prostatic hyperplasia (bph) treatment devices and equipment market was valued at about USD 0.9 billion in 2018 and is expected to grow to USD 1.13 billion at a CAGR of 5.9% through 2022. Benign Prostatic Hyperplasia (BPH) also called Prostate Gland Enlargement (PGE), is a condition where patient suffers from uncomfortable urinary symptoms. Due to rising prevalence of Benign Prostatic Hyperplasia (BPH), demand for the BPH treatment devices and equipment’s is on a steady rise as the number of BPH cases increases the demand for devices will also increase. For example, in the USA by 2018, more than 8 million men are suffering from Benign Prostatic Hyperplasia (BPH) and globally around 22 million men have been diagnosed with moderate to severe symptoms of BPH. Therefore, with number of BPH cases on the steady rise, the demand for BPH treatment devices and equipment is also expected to grow. The side effects suffered by the patients after a BPH procedure is one of the major restraints for BPH device and equipment market. For example, most common side effects of a BPH surgery includes, urinary incontinence, discomfort during urination and difficulty in completely emptying the bladder. The patients suffering from BPH does not prefer surgical procedures (till the stage it can be avoided) due to these side effects, therefore decreasing the demand of surgical procedures, which in turn limits the demand for devices used by end users like hospitals, clinics and ambulatory surgical centers. Prostatic Astery Embolization (PAE) is one of the latest developments in the market for Benign Prostatic Hyperplasia (BPH) treatment device and equipment. PAE is a minimally invasive treatment that assists in reducing the symptoms observed in urinary tract. The PAE procedure is done using X-rays and other advanced imaging to observe the tumor inside the body and accordingly treat it without any surgery. This technique results in reduced complication in the treatment of BPH and thus is said to be a major development in the market of BPH treatment. Leading companies such as Boston scientifics, UNC healthcare, and Spire healthcare have been investing in the market for PAE. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, the company bears all the cost of fixing the defective product and cost of replacement. This cost of replacement for large companies can go up to multi-million dollar, hence restraining the growth of the company and for the whole market as well. Product recall is one of the major hurdles for any market, Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment market is no exception. For example, in the year 2019, Procept BioRobotics Corporation recalled its AquaBeam Handpiece, a part of its AquaBeam Robotic System due to the possibility of developments of internal leak because of micro-cracks in specific weld joints within the product device. Also, in the year 2017, NXTHERA recalled its products like Rezum Systems and Vapor BPH Ablation System as the Needle Bond was not able to withstand the force when the needle was injected into and retracted from the prostate tissue in the treatment. In 2018, Boston Scientific acquired NxThera for an upfront cash payment of USD 306 million, and up to an additional USD 100 million in potential commercial milestone payments over the next four years. This acquisition will strengthen Boston’s already existing urology and pelvic health portfolio range. The acquisition of NxThera would be the best fit along with Boston Scientific’s laser therapy systems for the treatment of symptomatic BPH such as the Greenlight XPSTM Laser Therapy system and holmium platforms. NxThera, Inc.is involved in the manufacturing of medical devices to treat patients suffering from urologic conditions such as benign prostatic hyperplasia (BPH), prostate cancer, and kidney cancer. It was founded in 2008 and is headquartered in Minnesota, USA. Major players in the market are Karl Storz, Lumenis, Olympus, Urologix and Boston scientific Inc. Tags: global benign prostatic hyperplasia treatment devices and equipment market, global benign prostatic hyperplasia treatment devices and equipment market Analysis, global benign prostatic hyperplasia treatment devices and equipment market Forecast
